HAB-1, a new heteromyeloma for continuous production of human monoclonal antibodies.

To obtain suitable cell lines for the immortalisation of human lymphocytes, we constructed a heteromyeloma between the murine myeloma Ag8 and human lymphocytes from a highly malignant polymorphic, centroblastic B-cell lymphoma. The thioguanine-resistant and HAT-sensitive heteromyeloma HAB-1 neither...

Descripción completa

Detalles Bibliográficos
Autores principales: Faller, G., Vollmers, H. P., Weiglein, I., Marx, A., Zink, C., Pfaff, M., Müller-Hermelink, H. K.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1990
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971492/
https://www.ncbi.nlm.nih.gov/pubmed/2223577
_version_ 1782134922176102400
author Faller, G.
Vollmers, H. P.
Weiglein, I.
Marx, A.
Zink, C.
Pfaff, M.
Müller-Hermelink, H. K.
author_facet Faller, G.
Vollmers, H. P.
Weiglein, I.
Marx, A.
Zink, C.
Pfaff, M.
Müller-Hermelink, H. K.
author_sort Faller, G.
collection PubMed
description To obtain suitable cell lines for the immortalisation of human lymphocytes, we constructed a heteromyeloma between the murine myeloma Ag8 and human lymphocytes from a highly malignant polymorphic, centroblastic B-cell lymphoma. The thioguanine-resistant and HAT-sensitive heteromyeloma HAB-1 neither secretes nor contains cytoplasmatic immunoglobulins, the cells being EBV negative but positively stained for HLA-BC and the human proliferation marker Ki-67. The karyotype consists of about 50 murine and 20 human chromosomes. The HAB-1 cells grow in suspension and have a doubling rate of about 25-30 h. In fusion experiments with spleen cells from stomach carcinoma patients HAB-1 cells show a 5-7 times higher fusion efficiency than murine Ag8 cells or another heteromyeloma SPM4-0 and give stable antibody producing products. The cell line will be made available to interested scientists. IMAGES:
format Text
id pubmed-1971492
institution National Center for Biotechnology Information
language English
publishDate 1990
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19714922009-09-10 HAB-1, a new heteromyeloma for continuous production of human monoclonal antibodies. Faller, G. Vollmers, H. P. Weiglein, I. Marx, A. Zink, C. Pfaff, M. Müller-Hermelink, H. K. Br J Cancer Research Article To obtain suitable cell lines for the immortalisation of human lymphocytes, we constructed a heteromyeloma between the murine myeloma Ag8 and human lymphocytes from a highly malignant polymorphic, centroblastic B-cell lymphoma. The thioguanine-resistant and HAT-sensitive heteromyeloma HAB-1 neither secretes nor contains cytoplasmatic immunoglobulins, the cells being EBV negative but positively stained for HLA-BC and the human proliferation marker Ki-67. The karyotype consists of about 50 murine and 20 human chromosomes. The HAB-1 cells grow in suspension and have a doubling rate of about 25-30 h. In fusion experiments with spleen cells from stomach carcinoma patients HAB-1 cells show a 5-7 times higher fusion efficiency than murine Ag8 cells or another heteromyeloma SPM4-0 and give stable antibody producing products. The cell line will be made available to interested scientists. IMAGES: Nature Publishing Group 1990-10 /pmc/articles/PMC1971492/ /pubmed/2223577 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Faller, G.
Vollmers, H. P.
Weiglein, I.
Marx, A.
Zink, C.
Pfaff, M.
Müller-Hermelink, H. K.
HAB-1, a new heteromyeloma for continuous production of human monoclonal antibodies.
title HAB-1, a new heteromyeloma for continuous production of human monoclonal antibodies.
title_full HAB-1, a new heteromyeloma for continuous production of human monoclonal antibodies.
title_fullStr HAB-1, a new heteromyeloma for continuous production of human monoclonal antibodies.
title_full_unstemmed HAB-1, a new heteromyeloma for continuous production of human monoclonal antibodies.
title_short HAB-1, a new heteromyeloma for continuous production of human monoclonal antibodies.
title_sort hab-1, a new heteromyeloma for continuous production of human monoclonal antibodies.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971492/
https://www.ncbi.nlm.nih.gov/pubmed/2223577
work_keys_str_mv AT fallerg hab1anewheteromyelomaforcontinuousproductionofhumanmonoclonalantibodies
AT vollmershp hab1anewheteromyelomaforcontinuousproductionofhumanmonoclonalantibodies
AT weigleini hab1anewheteromyelomaforcontinuousproductionofhumanmonoclonalantibodies
AT marxa hab1anewheteromyelomaforcontinuousproductionofhumanmonoclonalantibodies
AT zinkc hab1anewheteromyelomaforcontinuousproductionofhumanmonoclonalantibodies
AT pfaffm hab1anewheteromyelomaforcontinuousproductionofhumanmonoclonalantibodies
AT mullerhermelinkhk hab1anewheteromyelomaforcontinuousproductionofhumanmonoclonalantibodies

Ejemplares similares